NYSE:HAE Haemonetics (HAE) Stock Price, News & Analysis $121.32 +1.18 (+0.98%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Haemonetics Stock (NYSE:HAE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Haemonetics alerts:Sign Up Key Stats Today's Range$119.00▼$121.1850-Day Range$101.32▼$121.9152-Week Range$49.96▼$123.77Volume197,913 shsAverage Volume805,413 shsMarket Capitalization$5.52 billionP/E Ratio59.47Dividend YieldN/APrice Target$110.00Consensus RatingModerate Buy Company Overview Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care. The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations. Haemonetics also provides technologies for surgical blood management, including systems that help hospitals collect, process, and reinfuse a patient’s own blood during procedures. Founded in 1971, Haemonetics serves customers in North America and international markets, including Europe and other regions. Its portfolio has included plasma collection platforms such as the PCS2 and NexSys systems, surgical blood-management products, and diagnostic technologies used to assess blood coagulation and guide transfusion decisions.AI Generated. May Contain Errors. Read More Haemonetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreHAE MarketRank™: 2.036213884165 of 5 starsHaemonetics scored higher than 41% of companies evaluated by MarketBeat, and ranked 660th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingHaemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and no sell ratings.Downside RiskHaemonetics has a consensus price target of $110.00, representing about 9.1% downside from its current price of $121.04.Amount of Analyst CoverageHaemonetics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Haemonetics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth8.32% Earnings GrowthEarnings for Haemonetics are expected to grow by 8.32% in the coming year, from $5.29 to $5.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Haemonetics is 59.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Haemonetics is 59.33, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.90.Price to Earnings Growth RatioHaemonetics has a PEG Ratio of 2.37. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHaemonetics has a P/B Ratio of 7.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Haemonetics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.69% of the float of Haemonetics has been sold short.Short Interest Ratio / Days to CoverHaemonetics has a short interest ratio ("days to cover") of 3.89, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Haemonetics has recently increased by 12.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHaemonetics does not currently pay a dividend.Dividend GrowthHaemonetics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.95 News SentimentHaemonetics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Haemonetics this week, compared to 5 articles on an average week.Search Interest9 people have searched for HAE on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows2 people have added Haemonetics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Haemonetics insiders have not sold or bought any company stock.Percentage Held by Insiders2.07% of the stock of Haemonetics is held by insiders.Percentage Held by Institutions99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Haemonetics' insider trading history. Receive HAE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HAE Stock News HeadlinesHere’s What Lifted Haemonetics (HAE) in Q31 hour ago | insidermonkey.comBlood plasma name hits highs on FDA approval as earnings loomOctober 28, 2026 | msn.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.November 3 at 1:00 AM | Decentralized Masters (Ad)Haemonetics Corporation (HAE) Gains on Strong Plasma Growth and Higher Guidance, Ariel Appreciation Fund SaysOctober 28, 2026 | insidermonkey.comHaemonetics Corporation (NYSE:HAE) Stock Has Average Price Target of $110.00 According to AnalystsOctober 27, 2026 | americanbankingnews.comHaemonetics consensus price target raised 24.88% to $145.63October 23, 2026 | msn.comHaemonetics Corporation Announces FDA Approval of Perqseal Elite Vascular Closure SystemOctober 20, 2026 | marketscreener.comMFDA Approves Haemonetics' PerQseal Elite For Large-Bore Arterial ProceduresOctober 20, 2026 | rttnews.comSee More Headlines HAE Stock Analysis - Frequently Asked Questions How have HAE shares performed this year? Haemonetics' stock was trading at $80.14 at the beginning of 2026. Since then, HAE shares have increased by 51.0% and is now trading at $121.0360. How were Haemonetics' earnings last quarter? Haemonetics Corporation (NYSE:HAE) posted its quarterly earnings results on Thursday, August, 6th. The medical instruments supplier reported $1.14 EPS for the quarter, beating the consensus estimate of $1.08 by $0.06. The company's revenue for the quarter was up 5.5% on a year-over-year basis. Read the conference call transcript. Who are Haemonetics' major shareholders? Haemonetics' top institutional investors include Assenagon Asset Management S.A. (1.00%), Fort Washington Investment Advisors Inc. OH (0.99%), Boston Trust Walden Corp (0.85%) and Isthmus Partners LLC (0.13%). Insiders that own company stock include Michelle L Basil, Anila Lingamneni, Josep Llorens and Stewart W Strong. View institutional ownership trends. How do I buy shares of Haemonetics? Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Haemonetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Haemonetics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Intel (INTC), Taiwan Semiconductor Manufacturing (TSM) and Abbott Laboratories (ABT). Company Calendar Last Earnings8/06/2026Today11/03/2026Next Earnings (Estimated)11/05/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 HAE's financial health is in the Green zone, according to TradeSmith. HAE has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:HAE CIK313143 Webwww.haemonetics.com Phone(781) 848-7100Fax781-848-5106Employees3,009Year Founded1971Price Target and Rating Average Price Target for Haemonetics$110.00 High Price Target$140.00 Low Price Target$78.00 Potential Upside/Downside-9.3%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$2.04 Trailing P/E Ratio59.47 Forward P/E Ratio21.17 P/E Growth2.37Net Income$97.31 million Net Margins7.12% Pretax Margin9.65% Return on Equity27.55% Return on Assets9.65% Debt Debt-to-Equity Ratio1.40 Current Ratio3.08 Quick Ratio1.91 Sales & Book Value Annual Sales$1.35 billion Price / Sales4.08 Cash Flow$7.77 per share Price / Cash Flow15.61 Book Value$17.14 per share Price / Book7.08Miscellaneous Outstanding Shares45,497,000Free Float44,555,000Market Cap$5.52 billion OptionableOptionable Beta0.62 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSE:HAE) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
